Table 2.
Comparison of published studies of gallbladder neuroendocrine carcinoma.
| First author [Ref.] | Chen Chen[7] | Anirban Maitra[36] | Jae-Myeong Lee[55] | Meenakshi Kamboj[28] | Shida Yan[5] |
| No. of cases | 10 | 12 | 12 | 19 | 15 |
| TNM stage | |||||
| I-II | 1 | NA | NA | 0 | 8 |
| III | 0 | NA | NA | 0 | 3 |
| IV | 9 | NA | NA | 19 | 4 |
| Histopathologic subtype | |||||
| NETs | NA | 0 | 1 | 0 | 0 |
| NECs | NA | 6 | 6 | 18 | 10 |
| MANECs | NA | 6 | 5 | 1 | 5 |
| Metastasis | LNs 7 | LNs 5, Liver 4, Periportal soft tissue 3 | NA | LNs 13, Liver 12, Omentum/Peritoneum 4, Ascites 3, Bone 2 | NA |
| Median survival time (mo) | 3.0 (1.8–23.3) | 9.0 (3.0–25.0) | 8.0 | 3.0 (1.0–9.5) | 20.4 (0.5–40.0) |
LN = lymph node, MANEC = mixed adeno-neuroendocrine carcinoma, NA = not available, NEC = neuroendocrine carcinoma, NET = neuroendocrine tumor, TNM = tumor-node-metastasis.